Confirmed SLE Diagnosis
Diagnosis per ACR/EULAR 2019 classification criteria
All Pathways
RheumatologyManagement
Systemic Lupus Erythematosus Management (ACR 2025)
Systemic Lupus Erythematosus Management (ACR 2025): Confirmed SLE Diagnosis → Universal Treatment for ALL SLE Patients → Assess Disease Activity → Gluco...
Pathway Overview
15 steps
Algorithm Steps
15 total
01Start 02Action Universal Treatment for ALL SLE Patients
Strong recommendation
- Hydroxychloroquine (HCQ) for ALL patients unless contraindicated
- HCQ dose: ≤5 mg/kg actual body weight/day
- Annual ophthalmologic screening after 5 years
- Sun protection and vitamin D supplementation
- Cardiovascular risk factor management
03Decision Assess Disease Activity
Evaluate organ involvement and severity
- Use validated tools: SLEDAI-2K, BILAG, PGA
- Target: Remission or LLDAS (Lupus Low Disease Activity State)
- Consider: skin, joints, serositis, hematologic, renal, CNS
04Action Glucocorticoid Management
Minimize use as much as possible (Strong)
- If on prednisone >5 mg/day: TAPER to ≤5 mg/day within 6 months
- Goal: prednisone ≤5 mg/day (ideally zero)
- Pulse IV methylpred for severe flares (then rapid taper)
- Add/escalate immunosuppression to enable GC reduction
05Warning ⚠️ Glucocorticoid Toxicity
Strong recommendation to minimize
- Long-term GC associated with damage accrual
- Increased infection, osteoporosis, AVN, diabetes
- Prednisone >5-7.5 mg/day associated with significant toxicity
- Add immunosuppression rather than increase GC
06Decision Moderate-Severe Disease?
Active disease despite HCQ ± mild immunosuppression
07Action Conventional Immunosuppression
Add to HCQ background
- Mycophenolate mofetil (MMF): 2-3g/day
- Azathioprine: 2-2.5 mg/kg/day (check TPMT first)
- Methotrexate: 15-25 mg/week (with folic acid)
- Cyclophosphamide: reserved for severe organ-threatening disease
08Decision Inadequate Response to Conventional IS?
Failure to achieve remission/LLDAS on HCQ + IS
09Action Biologic DMARDs
FDA-approved for SLE
- Belimumab (anti-BLyS): IV 10mg/kg q2wk x3 then q4wk, OR SC 200mg/wk
- Anifrolumab (anti-IFNAR): IV 300mg q4wk
- Continue HCQ and background IS with biologics
- May allow further GC reduction
10Action Organ-Specific Considerations
Specialized management by manifestation
- Lupus nephritis: See ACR 2024 LN guideline
- Neuropsychiatric lupus: High-dose GC + IS, consider rituximab
- Hematologic (ITP, AIHA): High-dose GC, rituximab, splenectomy
- Pulmonary: IS per severity; plasma exchange for DAH
11Action Refractory Disease
Failed multiple therapies
- Rituximab (off-label but widely used)
- Voclosporin (approved for LN)
- Combination biologic approaches (emerging)
- Clinical trial enrollment
- Specialist center referral
12Decision Remission/LLDAS Achieved?
Sustained for ≥6-12 months
13Outcome SLE Controlled
Maintain HCQ, consider cautious IS taper, regular monitoring
14Warning Specialist Center Referral
Refractory disease, severe organ involvement, clinical trial
- Path rejoins step 12Shared downstream outcome
- Path rejoins step 12Shared downstream outcome
15Action Mild Disease (Skin/Joints)
First-line for mild manifestations
- HCQ foundation (continue)
- Low-dose prednisone short-term if needed
- Methotrexate for arthritis/skin
- Topical agents for cutaneous lupus
- NSAIDs for arthralgia (caution in renal disease)
- Path rejoins step 06Shared downstream outcome
Guideline Source
2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Lupus nephritis addressed in separate ACR 2024 guideline
- Does not cover pediatric SLE comprehensively
- APS overlap requires separate management
- CNS lupus may require specialist input
- Drug availability varies by region
Applicable Regions
USEUAU
AU: ARA endorses ACR/EULAR recommendations
EU: EULAR 2023 also available
US: ACR 2025 is primary guidance
Version 1Next review: 2028-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Systemic Lupus Erythematosus Management (ACR 2025)?
The Systemic Lupus Erythematosus Management (ACR 2025) is a management clinical algorithm for Rheumatology. It provides a structured decision tree to guide clinical decision-making, based on 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus.
What guideline is the Systemic Lupus Erythematosus Management (ACR 2025) based on?
This algorithm is based on 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus (DOI: 10.1002/acr.25690).
What are the limitations of the Systemic Lupus Erythematosus Management (ACR 2025)?
Known limitations include: Lupus nephritis addressed in separate ACR 2024 guideline; Does not cover pediatric SLE comprehensively; APS overlap requires separate management; CNS lupus may require specialist input; Drug availability varies by region. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Systemic Lupus Erythematosus Management (ACR 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free